Compound Radar

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis

United States · Healthcare / Biotechnology

Price $56.71
Market cap $9.42B
Next earnings Nov 4, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

37
37/100 Avoid
  • Financial Health 30
  • Profitability 40
  • Business Quality 50
  • Balance Sheet 30
  • Cash Flow 40

Why this rating?

Health 37/100 — Avoid

Strongest Business Quality 50/100
Softest Balance Sheet 30/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Ionis Pharmaceuticals, Inc. (IONS) is a Biotechnology company in the Healthcare sector. Compound Radar rates Ionis Pharmaceuticals, Inc. 37/100 (Avoid) due to solid business quality and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Soft
  • Balance Sheet Stretched

Financial highlights

Valuation

  • Forward P/E -52.32
  • EV/Revenue 11.14

Profitability

  • Revenue Growth -40.7%
  • Gross Margin -6.9%
  • Operating Margin -38.2%
  • Net Margin -64.7%
  • ROE -105.5%

Financial strength

  • Cash $2.10B
  • Debt $2.19B
  • Net Cash $-86.67M
  • Free Cash Flow $-325.67M
  • Current Ratio 7.89

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Ionis Pharmaceuticals, Inc. (IONS).

View Methodology & FAQ →